Exelixis Inc (EXEL) Financial Statements
Historical financial data — 41 statements covering FY2016–FY2025
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic m...
Exelixis Inc's revenue increased 7.0% year over year, from $2.17B to $2.32B.
Net income increased 50.1% over the same period, from $521.3M to $782.6M.
Over the 9-year period from FY2016 to FY2025, revenue grew by 1112% in total.
Operating cash flow grew 26.3% to $884.3M.
Exelixis Inc maintains a strong net profit margin of 33.7%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2024 | $637.2M+49.8% | $226.1M | $619.5M | $275.9M | $119.5M | $2.77B | N/A | $2.12B |
| Q3 FY2024 | $539.5M-15.3% | $118.0M | $522.2M | $136.1M | $271.3M | $2.96B | N/A | $2.28B |
| Q4 FY2024 | $566.8M+5.0% | $139.9M | $546.8M | $163.2M | $240.3M | $2.95B | N/A | $2.24B |
| Q1 FY2025 | $555.4M-2.0% | $159.6M | $536.3M | $186.9M | $211.4M | $2.84B | N/A | $2.13B |
| Q2 FY2025 | $568.3M+2.3% | $184.8M | $548.8M | $213.6M | $49.0M | $2.68B | N/A | $2.03B |
| Q3 FY2025 | $597.8M+5.2% | $193.6M | $579.2M | $236.5M | $290.3M | $2.82B | N/A | $2.16B |
| Q4 FY2025 | $598.7M+0.2% | $244.5M | $572.2M | $235.2M | $333.5M | $2.84B | N/A | $2.16B |
| Q1 FY2026 | $610.8M+2.0% | $210.5M | $590.9M | $251.3M | $251.8M | $2.59B | N/A | $1.94B |
Balance Sheet Summary (Latest Period)
Exelixis Inc (EXEL) Financial Statements & Revenue History
Exelixis Inc (EXEL) is a US-listed stock operating in the Healthcare sector, specifically the Biological Products, (No Diagnostic Substances) industry trading at $58.15 with a market capitalization of $14. This page provides 41 historical financial statements for Exelixis Inc, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Exelixis Inc reported revenue of $2.3 billion, representing 7.0% year-over-year growth. The net profit margin of 33.7% reflects strong profitability..
EXEL Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Exelixis Inc's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether EXEL is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track EXEL's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Exelixis Inc converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of EXEL's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use EXEL Financial Data
Investors use Exelixis Inc's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare EXEL's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how EXEL's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View EXEL's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Exelixis Inc's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.EXEL trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.